# US 12,109,357 B2 · Blister pack and inhaler comprising the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,109,357 B2 - Document ID: US12109357B2 - Status: Granted - Kind: B2 - Application number: 18/052,649 - Filed: 2022-11-04 - Published: 2023-03-30 - Granted: 2024-10-08 - Earliest claimed: 2020-06-15 - Assignees: Norton (Waterford) Limited - Applicants: Norton (Waterford) Limited - Inventors: Peter John Crowley; Jan Geert Hazenberg; Daniel Buck; Christopher David Edlin; Hardik Kirtikumar Shah - Web page: https://patentgrep.com/patent/US12109357B2 ## CPC - A61M 15/0051: {the dosages being arranged on a tape, e.g. strips} - A61M 15/0003: {with means for dispensing more than one drug} - A61M 15/0021: {Mouthpieces therefor} - A61M 15/0025: {with caps} - A61M 15/0028: {using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up} - A61M 15/0043: {Non-destructive separation of the package, e.g. peeling} - A61M 15/0055: {the used dosages being coiled} - A61M 15/0026: {Hinged caps} - A61M 15/0035: {Piercing means} - A61M 15/0071: {having a display or indicator} - A61M 2202/064: Powder - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} ## Abstract Provided is a blister pack for a dry powder inhaler, which dry powder inhaler is configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets, e.g. respective blister pockets, of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments. This, in turn, may enable the depth/thickness of the dry powder inhaler to be minimized, and/or additional space to be provided inside the dry powder inhaler for accommodating, for example, use detection and wireless connectivity electronics for sending use detection data to an external device, such as a smartphone. ## Claims ### Claim 1 A dry powder inhaler configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament, the dry powder inhaler comprising: a blister pack; and a medicament delivery assembly, wherein the blister pack comprises: an elongated strip having blister pockets including a first series of blister pockets and a second series of blister pockets, wherein the first series and the second series are parallel with each other and extend along a length direction of the strip such that the first series and the second series overlap each other along the length direction, the first powder medicament being contained in the first series of blister pockets, and the second powder medicament being contained in the second series of blister pockets, wherein the strip is friable along a friable portion, the friable portion being elongated so as to have a length dimension extending along the length direction of the strip and arranged between the first series and the second series, and wherein the strip is folded along said friable portion to define a fold line extending in the length direction of the strip, wherein the medicament delivery assembly is configured to: separate the first series from the second series along the friable portion while the strip is folded along the friable portion by breaking the friable portion along the length dimension; and access the blister pockets to permit a subject to inhale the first and second powder medicaments therefrom. ### Claim 2 (depends on 1) The dry powder inhaler according to claim 1, wherein a first precursor strip comprising the first series is joined to a second precursor strip comprising the second series to form the strip. ### Claim 3 (depends on 1) The dry powder inhaler according to claim 1 further comprising: a mouthpiece, wherein the medicament delivery assembly comprises a manifold configured such that the first and second powder medicaments from the accessed blister pockets are drawn simultaneously therethrough and out of the mouthpiece when the subject inhales through the mouthpiece. ### Claim 4 (depends on 3) The dry powder inhaler according to claim 3, wherein the manifold comprises a first flow path along which the first powder medicament is carried towards the mouthpiece from one of the accessed blister pockets, and a second flow path along which the second powder medicament is carried towards the mouthpiece from the other of the accessed blister pockets. ### Claim 5 (depends on 1) The dry powder inhaler according to claim 1, wherein at least part of each of the blister pockets of the first series is aligned with a respective blister pocket of the second series. ### Claim 6 (depends on 1) The dry powder inhaler according to claim 1, wherein the medicament delivery assembly is configured to access at least one of said blister pockets of the first series and at least one of said blister pockets of the second series for each inhalation using the inhaler. ### Claim 7 (depends on 1) The dry powder inhaler according to claim 1, wherein the medicament delivery assembly is configured to separate the first series from the second series prior to accessing the respective blister pockets of the first series and the second series. ### Claim 8 (depends on 1) The dry powder inhaler according to claim 1, wherein the first series of blister pockets contain a different volume of the first powder medicament than a volume of the second powder medicament contained by the second series of blister pockets. ### Claim 9 (depends on 1) The dry powder inhaler according to claim 1, wherein the friable portion comprises a perforation extending along the length direction of the strip and arranged between the first series and the second series. ### Claim 10 (depends on 1) The dry powder inhaler according to claim 1, wherein the first series and the second series are formed integrally in the strip. ### Claim 11 (depends on 1) The dry powder inhaler according to claim 1, wherein the blister pack further comprises a peelable cover for covering the blister pockets, wherein the blister pockets are defined in a base layer, and wherein the peelable cover is releasably adhered to the base layer between the blister pockets. ### Claim 12 (depends on 1) The dry powder inhaler according to claim 1, wherein the medicament delivery assembly is configured to advance the strip by pulling or by pushing the strip. ### Claim 13 (depends on 1) The dry powder inhaler according to claim 1, wherein: the first powder medicament comprises budesonide and the second powder medicament comprises formoterol; or the first powder medicament comprises beclomethasone and the second powder medicament comprises formoterol; or the first powder medicament comprises fluticasone and the second powder medicament comprises salmeterol, or the first powder medicament comprises fluticasone and the second powder medicament comprises albuterol, or the first powder medicament comprises fluticasone and the second powder medicament comprises vilanterol, or the first powder medicament comprises umeclidinium and the second powder medicament comprises vilanterol, or the first powder medicament comprises two selected from umeclidinium, fluticasone and vilanterol, and the second powder medicament comprises the remaining medicament from umeclidinium, fluticasone and vilanterol not selected for the first powder medicament. ### Claim 14 (depends on 1) The dry powder inhaler according to claim 1, wherein: the first powder medicament comprises fluticasone furoate and the second powder medicament comprises vilanterol trifenatate, or the first powder medicament comprises umeclidinium bromide and the second powder medicament comprises vilanterol trifenatate, or the first powder medicament comprises two selected from umeclidinium bromide, fluticasone furoate and vilanterol trifenatate, and the second powder medicament comprises the remaining medicament from umeclidinium bromide, fluticasone furoate and vilanterol trifenatate not selected for the first powder medicament. ### Claim 15 A dry powder inhaler configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament, the dry powder inhaler comprising: a blister pack; and a medicament delivery assembly, wherein the blister pack comprises: blister pockets including a first series of blister pockets and a second series of blister pockets; and a first base layer in which the first series of blister pockets are defined, and a second base layer in which the second series of blister pockets are defined, the first powder medicament being contained in the first series of blister pockets, and the second powder medicament being contained in the second series of blister pockets, wherein the blister pack further comprises a unitary cover for covering the first series of blister pockets and the second series of blister pockets, wherein the unitary cover comprises a first surface and a second surface facing away from the first surface, wherein the first surface and the second surface are opposite surfaces of the unitary cover, and the unitary cover is formed as a single web of material, such that the first surface and the second surface cannot be moved apart, the first series of blister pockets being covered by the first surface of the unitary cover, and the second series of blister pockets being covered by the second surface of the unitary cover, wherein the medicament delivery assembly is configured to: access the blister pockets and permit a subject to inhale the first and second powder medicaments therefrom. ### Claim 16 (depends on 15) The dry powder inhaler according to claim 15, wherein the first base layer and the second base layer are peelable base layers, and the unitary cover is a peelable cover, and the first surface is releasably adhered to the first base layer between the first series of blister pockets, and the second surface is releasably adhered to the second base layer between the second series of blister pockets, and wherein the medicament delivery assembly comprises a peeling mechanism configured to peel the first base layer and the second base layer from the unitary cover thereby to expose the first and second powder medicaments. ### Claim 17 (depends on 16) The dry powder inhaler according to claim 16, wherein the peeling mechanism is configured to peel the first base layer and the second base layer simultaneously from the unitary cover. ### Claim 18 (depends on 16) The dry powder inhaler according to claim 16, wherein the peeling mechanism is configured to peel the first base layer from the unitary cover and subsequently peel the second base layer from the unitary cover, or wherein the peeling mechanism is configured to peel the second base layer from the unitary cover and subsequently peel the first base layer from the unitary cover. ### Claim 19 (depends on 15) The dry powder inhaler according to claim 15, further comprising a mouthpiece, wherein the medicament delivery assembly comprises a manifold configured such that the first and second powder medicaments from the accessed blister pockets are drawn simultaneously therethrough and out of the mouthpiece when the subject inhales through the mouthpiece. ### Claim 20 (depends on 19) The dry powder inhaler according to claim 19, wherein the manifold comprises a first flow path along which the first powder medicament is carried towards the mouthpiece from one of the accessed blister pockets, and a second flow path along which the second powder medicament is carried towards the mouthpiece from another of the accessed blister pockets. ### Claim 21 (depends on 15) The dry powder inhaler according to claim 15, wherein the medicament delivery assembly is configured to access at least one of blister pocket of the first series of blister pockets and at least one blister pocket of the second series of blister pockets for each inhalation using the inhaler. ### Claim 22 (depends on 15) The dry powder inhaler according to claim 15, wherein the first series of blister pockets are aligned with the second series of blister pockets. ### Claim 23 (depends on 15) The dry powder inhaler according to claim 15, wherein the first series of blister pockets are offset relative to the second series of blister pockets. ### Claim 24 (depends on 15) The dry powder inhaler according to claim 15, wherein the first series of blister pockets and the second series of blister pockets can be accessed via a rupturing, puncturing and/or tearing mechanism. ### Claim 25 (depends on 15) The dry powder inhaler according to claim 15, wherein the medicament delivery assembly is not capable of moving the first surface and the second surface of the unitary cover apart. ### Claim 26 (depends on 15) The dry powder inhaler according to claim 15, wherein all layers of the unitary cover are permanently attached to each other, apart from any layers of adhesive present on the outermost surfaces.